Identification

Name
Sotalol
Accession Number
DB00489  (APRD01230)
Type
Small Molecule
Groups
Approved
Description

An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]

Structure
Thumb
Synonyms
  • 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
  • Sotalol
  • Sotalolo
  • Sotalolum
External IDs
MJ 1999
Product Ingredients
IngredientUNIICASInChI Key
Sotalol HydrochlorideHEC37C70XX959-24-0VIDRYROWYFWGSY-UHFFFAOYNA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-sotalolTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-sotalolTablet160 mgOralAvanstra Inc2011-08-112014-08-21Canada
BetapaceTablet80 mg/1OralBayer1992-10-30Not applicableUs50419 0105 10 nlmimage10 16190b68
BetapaceTablet120 mg/1OralCovis Pharma2016-09-01Not applicableUs
BetapaceTablet160 mg/1OralBayer1992-10-30Not applicableUs50419 0106 10 nlmimage10 10190868
BetapaceTablet80 mg/1OralCovis Pharma2016-09-01Not applicableUs
BetapaceTablet120 mg/1OralBayer1992-10-30Not applicableUs50419 0109 10 nlmimage10 19190cb8
BetapaceTablet160 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet160 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet80 mg/1OralBayer2000-02-22Not applicableUs50419 0115 06 nlmimage10 56192b19
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sotalol - Tab 160mgTablet160 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-sotalol 80mg TabletsTablet80 mgOralApotex Corporation1996-12-31Not applicableCanada
SorineTablet160 mg/1OralUpsher Smith Laboratories2011-02-15Not applicableUs
SorineTablet80 mg/1OralUpsher Smith Laboratories2011-02-15Not applicableUs
SorineTablet240 mg/1OralUpsher Smith Laboratories2011-02-15Not applicableUs
SorineTablet80 mg/1OralCardinal Health2011-02-15Not applicableUs
SorineTablet120 mg/1OralUpsher Smith Laboratories2011-02-15Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralGolden State Medical Supply2003-02-01Not applicableUs60505 0082 00 nlmimage10 2e331718
Sotalol HydrochlorideTablet160 mg/1OralQualitest2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralPd Rx Pharmaceuticals, Inc.2000-05-01Not applicableUs
International/Other Brands
beta-Cardone / Biosotal (Sanofi-Aventis) / Cardol (Alphapharm) / Darob (Abbott) / Darob mite (Abbott) / Hipecor (Merck) / Loritmik (Krka) / Rytmobeta (Abbott) / Sotacor (Bristol-Myers Squibb) / Sotagard (GlaxoSmithKline) / Sotalex (Bristol-Myers Squibb) / Sotapor (Bristol-Myers Squibb) / Talozin (Adeka) / Tan Shi (Chia Tai Tianqing) / Xi An Lin (Changzhou Pharmaceutical Factory)
Categories
UNII
A6D97U294I
CAS number
3930-20-9
Weight
Average: 272.364
Monoisotopic: 272.119463206
Chemical Formula
C12H20N2O3S
InChI Key
ZBMZVLHSJCTVON-UHFFFAOYSA-N
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
IUPAC Name
N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
SMILES
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1

Pharmacology

Indication

For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.

Structured Indications
Pharmacodynamics

Sotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.

Mechanism of action

Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.

TargetActionsOrganism
APotassium voltage-gated channel subfamily H member 2
inhibitor
Human
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
Absorption

In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.

Volume of distribution
Not Available
Protein binding

Sotalol does not bind to plasma proteins.

Metabolism

Sotalol is not metabolized.

Route of elimination

Excretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.

Half life

Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.

Clearance
Not Available
Toxicity

The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Sotalol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Sotalol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Sotalol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Sotalol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Sotalol.Approved
AcetohexamideSotalol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetylcholine.Approved
AcetyldigitoxinSotalol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinSotalol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Sotalol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Sotalol.Experimental, Investigational
AlaproclateThe serum concentration of Sotalol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Sotalol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Sotalol.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
AlgeldrateThe serum concentration of Sotalol can be decreased when it is combined with Algeldrate.Experimental
AlimemazineAlimemazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.Approved, Investigational
AlmagateThe serum concentration of Sotalol can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Sotalol can be decreased when it is combined with Almasilate.Experimental
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Sotalol.Experimental
AloglutamolThe serum concentration of Sotalol can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Sotalol can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Sotalol can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Sotalol can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Sotalol.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Sotalol.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Sotalol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Sotalol is combined with Amiloride.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Sotalol.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Sotalol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Sotalol.Approved, Illicit
AmodiaquineThe metabolism of Sotalol can be decreased when combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Sotalol.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sotalol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Sotalol is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Sotalol.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Sotalol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Sotalol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Sotalol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Sotalol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Sotalol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Sotalol is combined with Arecoline.Experimental
ArformoterolArformoterol may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sotalol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sotalol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sotalol.Approved, Investigational
ArtemetherSotalol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineSotalol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Sotalol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Sotalol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Sotalol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Sotalol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Sotalol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Sotalol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Sotalol.Experimental
BarbitalBarbital may increase the hypotensive activities of Sotalol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sotalol.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Sotalol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Sotalol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.Approved
BenorilateBenorilate may decrease the antihypertensive activities of Sotalol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Sotalol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sotalol.Approved, Withdrawn
BeractantSotalol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sotalol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Sotalol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Sotalol.Experimental
Bismuth SubcitrateThe serum concentration of Sotalol can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Sotalol can be decreased when it is combined with Bismuth subnitrate.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Sotalol.Investigational
BortezomibBortezomib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Sotalol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Sotalol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Sotalol.Investigational
BucindololSotalol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Sotalol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Sotalol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.Approved
BunazosinSotalol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Sotalol.Approved
CabergolineSotalol may increase the vasoconstricting activities of Cabergoline.Approved
Calcium CarbonateThe serum concentration of Sotalol can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Sotalol can be decreased when it is combined with Calcium silicate.Experimental
CalfactantSotalol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Sotalol.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sotalol.Approved
CarbutamideSotalol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.Approved
CarvedilolSotalol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Sotalol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
CeritinibSotalol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Sotalol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Sotalol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sotalol.Approved, Vet Approved
ChlorpropamideSotalol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Sotalol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sotalol.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
CisaprideSotalol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Sotalol.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Sotalol.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sotalol.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Sotalol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sotalol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Sotalol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Sotalol.Vet Approved
CrizotinibSotalol may increase the bradycardic activities of Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Sotalol.Investigational
CymarinSotalol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Sotalol.Investigational
DabrafenibDabrafenib may increase the QTc-prolonging activities of Sotalol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Sotalol can be increased when it is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Sotalol.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Sotalol.Approved
DemecariumDemecarium may increase the bradycardic activities of Sotalol.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Sotalol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Sotalol.Approved
DeslanosideSotalol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Sotalol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Sotalol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Diclofenamide.Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Sotalol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Sotalol.Approved
DigitoxinSotalol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Sotalol.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Sotalol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Sotalol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Sotalol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Sotalol.Approved
DistigmineDistigmine may increase the bradycardic activities of Sotalol.Experimental
DofetilideDofetilide may increase the QTc-prolonging activities of Sotalol.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Sotalol.Approved
DomperidoneSotalol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Sotalol.Approved
DoxazosinSotalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Sotalol.Approved
DronedaroneDronedarone may increase the bradycardic activities of Sotalol.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Sotalol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
DuloxetineSotalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Sotalol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Sotalol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Sotalol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Sotalol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sotalol.Approved
EliglustatSotalol may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sotalol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Sotalol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sotalol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.Approved
Ergoloid mesylateSotalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineSotalol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
EscitalopramSotalol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Sotalol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Sotalol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Sotalol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Sotalol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Sotalol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
EtoperidoneThe serum concentration of Sotalol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Sotalol.Approved
exisulindexisulind may decrease the antihypertensive activities of Sotalol.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Sotalol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Sotalol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Sotalol.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Sotalol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Sotalol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sotalol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Sotalol.Approved
FentanylFentanyl may increase the bradycardic activities of Sotalol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Sotalol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Sotalol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Sotalol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Sotalol.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sotalol.Approved
FingolimodSotalol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Sotalol.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sotalol.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Sotalol.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Sotalol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Sotalol.Experimental
FluoxetineThe serum concentration of Sotalol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolSotalol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Sotalol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Sotalol.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Sotalol.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.Approved, Vet Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Sotalol.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Sotalol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Sotalol.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Sotalol.Approved, Nutraceutical
GitoformateSotalol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideSotalol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideSotalol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideSotalol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneSotalol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideSotalol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideSotalol may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Sotalol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Sotalol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Sotalol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Sotalol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sotalol.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Sotalol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Sotalol.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Sotalol.Approved
Huperzine AHuperzine A may increase the bradycardic activities of Sotalol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sotalol.Approved
HydrotalciteThe serum concentration of Sotalol can be decreased when it is combined with Hydrotalcite.Experimental
HydroxychloroquineThe metabolism of Sotalol can be decreased when combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Sotalol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Sotalol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Sotalol.Withdrawn
IbutilideIbutilide may increase the QTc-prolonging activities of Sotalol.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Sotalol.Approved
IloperidoneSotalol may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Sotalol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sotalol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Sotalol.Experimental
ImipramineImipramine may increase the QTc-prolonging activities of Sotalol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Sotalol.Approved
IndalpineThe serum concentration of Sotalol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Sotalol.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Sotalol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Sotalol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Sotalol.Withdrawn
IndoraminSotalol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkSotalol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Sotalol.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sotalol.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Sotalol.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Sotalol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Sotalol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Sotalol.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
IvabradineSotalol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Sotalol.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Sotalol.Approved
LabetalolSotalol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sotalol.Approved
LacosamideSotalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CSotalol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideSotalol may increase the bradycardic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Sotalol.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Sotalol.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sotalol.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Sotalol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sotalol.Approved
LevodopaSotalol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LevomilnacipranThe serum concentration of Sotalol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Sotalol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Sotalol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Sotalol.Investigational
LithiumLithium may increase the QTc-prolonging activities of Sotalol.Approved
LobelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Sotalol.Experimental
LopinavirSotalol may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Sotalol.Approved
LosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Sotalol.Approved
LucinactantSotalol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineSotalol may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
MagaldrateThe serum concentration of Sotalol can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium HydroxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Sotalol.Approved
Magnesium silicateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.Approved
MalathionMalathion may increase the bradycardic activities of Sotalol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Sotalol.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Sotalol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Sotalol.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Sotalol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Sotalol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Sotalol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Sotalol.Approved
MetahexamideSotalol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Sotalol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Methacholine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Sotalol.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Sotalol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Sotalol.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Sotalol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Sotalol.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Sotalol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Sotalol.Investigational
MethylergometrineSotalol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Sotalol.Approved
MetildigoxinSotalol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sotalol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Sotalol.Approved
MidodrineSotalol may increase the bradycardic activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MilnacipranThe serum concentration of Sotalol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Sotalol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sotalol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Sotalol.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Sotalol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Sotalol.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Sotalol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Sotalol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Sotalol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sotalol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Sotalol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Sotalol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Sotalol.Approved
NadololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Sotalol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Sotalol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Sotalol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Sotalol.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Sotalol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Sotalol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Sotalol is combined with Nesiritide.Approved, Investigational
NicardipineNicardipine may increase the QTc-prolonging activities of Sotalol.Approved
NicorandilNicorandil may increase the hypotensive activities of Sotalol.Approved
NicotineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Sotalol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Sotalol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Sotalol.Approved
NilotinibSotalol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sotalol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Sotalol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sotalol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Sotalol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Sotalol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sotalol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
OleandrinSotalol may increase the bradycardic activities of Oleandrin.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Sotalol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Sotalol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Sotalol.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Sotalol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Sotalol.Vet Approved
OuabainSotalol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Sotalol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sotalol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Sotalol.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sotalol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Sotalol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Sotalol.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Sotalol.Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Sotalol.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Sotalol.Approved
PenbutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Sotalol.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Sotalol.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Sotalol.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Sotalol.Approved
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Sotalol.Approved
PeruvosideSotalol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sotalol.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Sotalol.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sotalol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Sotalol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Sotalol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Sotalol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Sotalol.Approved, Investigational
PimozideSotalol may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Sotalol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sotalol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Sotalol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Sotalol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Sotalol.Experimental
Poractant alfaSotalol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sotalol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Sotalol.Experimental
PrazosinSotalol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Sotalol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ProcainamideSotalol may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Sotalol.Experimental
PromazinePromazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Sotalol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Sotalol.Approved
PropafenoneThe serum concentration of Sotalol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Sotalol.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Sotalol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Sotalol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Sotalol.Experimental
ProscillaridinSotalol may increase the bradycardic activities of Proscillaridin.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Sotalol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Sotalol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Sotalol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Sotalol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.Approved, Investigational
QuinidineSotalol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Sotalol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sotalol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Sotalol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sotalol.Approved
ReserpineReserpine may increase the hypotensive activities of Sotalol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Sotalol.Experimental, Investigational
RifampicinThe serum concentration of Sotalol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Sotalol can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Sotalol.Approved
RiociguatThe risk or severity of adverse effects can be increased when Sotalol is combined with Riociguat.Approved
RisperidoneSotalol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Sotalol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Sotalol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sotalol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Sotalol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Sotalol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sotalol.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Sotalol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Sotalol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Sotalol.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Sotalol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sotalol.Approved, Investigational, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Sotalol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Sotalol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Sotalol.Investigational
SertralineSertraline may increase the QTc-prolonging activities of Sotalol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
SilodosinSotalol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Sotalol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Sotalol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Sotalol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.Approved
SufentanilSotalol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Sotalol.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Sotalol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Sotalol.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Sotalol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Sotalol.Experimental
TacrineTacrine may increase the bradycardic activities of Sotalol.Withdrawn
TamoxifenTamoxifen may increase the QTc-prolonging activities of Sotalol.Approved
TamsulosinSotalol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Sotalol.Investigational
TelavancinTelavancin may increase the QTc-prolonging activities of Sotalol.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Sotalol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.Approved, Investigational
TenidapTenidap may decrease the antihypertensive activities of Sotalol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Sotalol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Sotalol.Vet Approved
TerazosinSotalol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Sotalol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Sotalol.Approved
TetrabenazineSotalol may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sotalol.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Sotalol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sotalol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sotalol.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Sotalol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Sotalol.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Sotalol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Sotalol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Sotalol.Approved, Investigational
TolazamideSotalol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Sotalol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sotalol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Sotalol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Sotalol.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.Approved
ToremifeneSotalol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Sotalol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sotalol.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Sotalol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Sotalol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Sotalol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Sotalol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
TrimazosinSotalol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Sotalol.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Sotalol.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
TubocurarineTubocurarine may increase the bradycardic activities of Sotalol.Approved
UrapidilSotalol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Sotalol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.Approved, Investigational
VandetanibSotalol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Sotalol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Sotalol is combined with Varenicline.Approved, Investigational
VemurafenibSotalol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Sotalol.Approved
VerapamilThe risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Sotalol.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Sotalol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Sotalol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Sotalol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Sotalol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Sotalol.Withdrawn
ZuclopenthixolSotalol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7-12. [PubMed:8691967]
External Links
Human Metabolome Database
HMDB14632
KEGG Compound
C07309
PubChem Compound
5253
PubChem Substance
46505012
ChemSpider
5063
BindingDB
25762
ChEBI
63622
ChEMBL
CHEMBL471
Therapeutic Targets Database
DAP000372
PharmGKB
PA451457
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sotalol
ATC Codes
C07AA57 — Sotalol, combinationsC07AA07 — SotalolC07BA07 — Sotalol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (93.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1TerminatedBasic ScienceNonvalvular Atrial Fibrillation1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction (MI) / Severe ventricular arrhythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Diseases / Severe ventricular arrhythmias / Ventricular Arrythmias / Ventricular Tachycardia (VT)1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Diseases / Severe ventricular arrhythmias / Ventricular Tachycardia (VT)1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentCerebrovascular Accidents / Nonvalvular Atrial Fibrillation / Sudden Death1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentParoxysmal Atrial Fibrillation (PAF)1
3Enrolling by InvitationTreatmentFetal Atrial Flutter Without Hydrops / Fetal Supraventricular Tachycardia With Hydrops / Fetal Supraventricular Tachycardia Without Hydrops1
3SuspendedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4Active Not RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4RecruitingTreatmentMyocardial Infarction (MI) / Ventricular Tachyarrhythmias1
4WithdrawnTreatmentNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified / Recurrent Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentVentricular Tachycardia (VT)1

Pharmacoeconomics

Manufacturers
  • Academic pharmaceuticals inc
  • Bayer healthcare pharmaceuticals inc
  • Upsher smith laboratories inc
  • Amneal pharmaceutical
  • Apotex inc
  • Apotex inc etobicoke site
  • Impax pharmaceuticals
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral160 mg
TabletOral80 mg
TabletOral240 mg
InjectionIntravenous15 mg/mL
TabletOral120 mg/1
TabletOral160 mg/1
TabletOral240 mg/1
TabletOral80 mg/1
SolutionOral5 mg/mL
Prices
Unit descriptionCostUnit
Betapace AF 100 160 mg tablet Box538.2USD box
Betapace AF 60 120 mg tablet Bottle311.06USD bottle
Betapace 240 mg tablet8.94USD tablet
Sotalol hcl 150 mg/10 ml vial7.8USD ml
Betapace 160 mg tablet6.87USD tablet
Betapace af 160 mg tablet6.24USD tablet
Sorine 240 mg tablet5.6USD tablet
Betapace 120 mg tablet5.5USD tablet
Sotalol HCl 240 mg tablet5.29USD tablet
Sotalol 240 mg tablet5.09USD tablet
Betapace af 120 mg tablet4.99USD tablet
Sotalol HCl (AF) 160 mg tablet4.45USD tablet
Sorine 160 mg tablet4.31USD tablet
Sotalol af 160 mg tablet4.27USD tablet
Betapace 80 mg tablet4.12USD tablet
Sotalol HCl 160 mg tablet4.07USD tablet
Sotalol 160 mg tablet3.92USD tablet
Betapace af 80 mg tablet3.74USD tablet
Sotalol HCl (AF) 120 mg tablet3.56USD tablet
Sorine 120 mg tablet3.46USD tablet
Sotalol af 120 mg tablet3.42USD tablet
Sotalol HCl 120 mg tablet3.26USD tablet
Sotalol 120 mg tablet3.13USD tablet
Sotalol HCl 80 mg tablet2.67USD tablet
Sotalol HCl (AF) 80 mg tablet2.67USD tablet
Sorine 80 mg tablet2.61USD tablet
Sotalol af 80 mg tablet2.56USD tablet
Sotalol 80 mg tablet2.35USD tablet
Apo-Sotalol 160 mg Tablet0.68USD tablet
Co Sotalol 160 mg Tablet0.68USD tablet
Mylan-Sotalol 160 mg Tablet0.68USD tablet
Novo-Sotalol 160 mg Tablet0.68USD tablet
Nu-Sotalol 160 mg Tablet0.68USD tablet
Pms-Sotalol 160 mg Tablet0.68USD tablet
Ratio-Sotalol 160 mg Tablet0.68USD tablet
Sandoz Sotalol 160 mg Tablet0.68USD tablet
Apo-Sotalol 80 mg Tablet0.62USD tablet
Co Sotalol 80 mg Tablet0.62USD tablet
Mylan-Sotalol 80 mg Tablet0.62USD tablet
Novo-Sotalol 80 mg Tablet0.62USD tablet
Nu-Sotalol 80 mg Tablet0.62USD tablet
Pms-Sotalol 80 mg Tablet0.62USD tablet
Ratio-Sotalol 80 mg Tablet0.62USD tablet
Sandoz Sotalol 80 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)206.5-207 °CPhysProp
water solubilitySoluble (5510 mg/L)Not Available
logP0.24BURGOT,G ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.782 mg/mLALOGPS
logP0.85ALOGPS
logP-0.4ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.12 m3·mol-1ChemAxon
Polarizability29.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6708
P-glycoprotein inhibitor INon-inhibitor0.8881
P-glycoprotein inhibitor IINon-inhibitor0.9638
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7392
CYP450 2D6 substrateNon-substrate0.8296
CYP450 3A4 substrateNon-substrate0.6194
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8276
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.587
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2873 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.846
hERG inhibition (predictor II)Non-inhibitor0.8701
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-b3dca1dbda7d2457ee97
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-a29ae691c7c3aac0cd25
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-3826232ebd5c11e1fb09
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-0590000000-c1cd421f642943a3e40d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-62e0058eee644436c974
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-1c2e1183f392f02dd2f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0900000000-467f723fa9c5b11ac3a0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-ec702c0822212cb2e764
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-3fe820b16cdb741dfa3e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-0090000000-ba1b9c76db4e9239d8ff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-9855a87a9a317eccb37e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03e9-0690000000-0c5b752605586d60828a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0910000000-399c8ea4647bc5a24781
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-f44d2d18cd4dfd9b2756
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-053r-0900000000-422f178f83cadcda84d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-0090000000-06e3079747baad9d6087
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-69df046b345e5e50d742
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03e9-0690000000-94ba050da9e6a24f29b1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0910000000-0ef0a4777ff5e99c8462
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-52c0f117b0c8ef4e0b76
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-053r-0900000000-ade6b1782a916acc1d7e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-ef1bcb821ca9cd1627a8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-75d846e48f9d41af615c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03e9-0790000000-610bf5222b1cb6f67b93
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-053r-0900000000-943fd2d5d938aa51d8d5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0920000000-7400cd81d8ca70325a62
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-053r-0900000000-3b49e7b47aa69566cb3a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-36ad35b8c37f5c9f4e91
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-1f8f59e1c29a48907b1d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0390000000-7e44e05711b4dc722309

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Sulfanilides
Direct Parent
Sulfanilides
Alternative Parents
Aralkylamines / Organosulfonamides / Organic sulfonamides / Aminosulfonyl compounds / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Sulfanilide / Aralkylamine / Organic sulfonic acid amide / Organosulfonic acid amide / Aminosulfonyl compound / Sulfonyl / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Secondary alcohol / 1,2-aminoalcohol
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfonamide, secondary alcohol, secondary amino compound, ethanolamines (CHEBI:63622)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000 Aug 8;102(6):706-12. [PubMed:10931813]
  2. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res. 2000 Nov 24;87(11):1012-8. [PubMed:11090546]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388]
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. [PubMed:16076272]
  5. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. [PubMed:16686685]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:23